Advertisement
DXCM vs ISRG
Which Stock Would AI Choose? DexCom (DXCM) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- ISRG has outperformed DXCM year-to-date (YTD, year-to-date) with +16.84% returns compared to +7.47%.
- DXCM trades at a lower price-to-earnings (PE) ratio of 29.38 versus ISRG's 57.16, indicating relative valuation appeal.
- Both medtech leaders show resilience amid sector volatility, with ISRG benefiting from recent Q1 earnings beat featuring 23% revenue growth.
- DXCM nears its 52-week low amid share weakness, ahead of Q1 earnings with projected 13.6% revenue growth from G7 continuous glucose monitoring (CGM) sensor uptake.
- ISRG's larger market cap of $167B dwarfs DXCM's $24B, reflecting scale in robotic surgery.
- Technical analysis scores are balanced, with both stocks showing four bullish indicators each.
Introduction
DexCom (DXCM) and Intuitive Surgical (ISRG) represent innovative leaders in medical technology, focusing on continuous glucose monitoring for diabetes management and robotic-assisted surgery, respectively. This stock comparison analyzes their recent market positioning, performance, and growth drivers in the current healthcare landscape. Growth-oriented investors and traders tracking medtech relative performance will find insights into momentum, valuation trade-offs, and sector sentiment shifts valuable for portfolio decisions.
DXCM Overview and Recent Performance
DexCom (DXCM) develops CGM systems, generating recurring revenue from disposable sensors. In recent market activity, shares have traded near the 52-week low of $54.11 around $61.41, reflecting a pullback despite solid fundamentals. The stock experienced weakness post-Q4 2025 earnings beat, where revenue grew 13% and full-year guidance was reiterated amid G7 sensor rollout momentum. Sentiment has been influenced by competition from GLP-1 weight-loss drugs and broader medtech sector pressures, though analysts maintain Buy ratings with a $87 average price target. Upcoming Q1 2026 results, due April 30, project 13.6% year-over-year revenue growth, potentially supporting recovery if G7 adoption accelerates.
ISRG Overview and Recent Performance
Intuitive Surgical (ISRG) dominates robotic surgery with its da Vinci systems, deriving revenue from capital equipment and recurring instruments/services. Shares recently closed at $470.99, down from a 52-week high of $603.88 but up 16.84% YTD. Q1 2026 earnings exceeded expectations with $2.77 billion in revenue, a 23% increase driven by procedure growth, and adjusted EPS of $2.50. Recent weeks saw some volatility amid analyst target adjustments, yet Strong Buy consensus prevails with a $577 price target. Procedure volume expansion and global adoption have bolstered sentiment, offsetting high PE concerns in a high-growth context.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across diverse strategies, timeframes, and market conditions. Only the most suitable for prevailing volatility and trends earn a spot among the 25 featured, displaying key metrics like win rate, profit factor, average return, Sharpe ratio (a measure of risk-adjusted performance), and maximum drawdown. Bots vary from short-term scalpers on 5-minute charts to longer-term swing traders, with performance stats highlighting consistency—many exhibit profit factors above 1.5 and attractive Sharpe ratios. These tools adapt to current market dynamics, offering data-driven signals without emotional bias. Explore Trending AI Robots to identify bots matching your risk tolerance and timeframe.
Head-to-Head Comparison
DXCM and ISRG both thrive in medtech but differ in business models: DXCM's sensor consumables yield high recurring revenue (over 80% of sales), while ISRG balances system sales with instrument utilization fees. Growth drivers contrast with DXCM expanding CGM adoption amid diabetes prevalence versus ISRG's reliance on surgical procedure volumes, which grew robustly in recent quarters. Momentum favors ISRG with stronger YTD gains and earnings catalysts, while DXCM offers value at lower multiples amid near-term weakness. Risks include reimbursement pressures for DXCM and competition in robotics for ISRG; sentiment tilts positive for both per analyst views, with shared healthcare sector exposure.
Tickeron AI Verdict
Tickeron's AI currently leans toward ISRG based on superior recent momentum, Q1 earnings outperformance, YTD relative strength, and consistent procedure growth positioning it favorably in medtech trends. While DXCM presents valuation upside ahead of earnings, ISRG's stability and catalysts suggest higher probability of near-term outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DXCM is a StrongBuy and ISRG is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 1 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- DXCM’s FA Score: 1 green, 4 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 6 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s).
- DXCM’s TA Score: 6 bullish, 4 bearish.
- ISRG’s TA Score: 4 bullish, 4 bearish.
Price Growth
DXCM (@Medical/Nursing Services) experienced а -5.80% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -3.26% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.52%. For the same industry, the average monthly price growth was -4.27%, and the average quarterly price growth was -16.56%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.
Reported Earning Dates
DXCM is expected to report earnings on Jul 23, 2026.
ISRG is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.52% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-2.31% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DXCM | ISRG | DXCM / ISRG | |
| Capitalization | 26.6B | 143B | 19% |
| EBITDA | 1.48B | 3.95B | 37% |
| Gain YTD | 3.842 | -28.853 | -13% |
| P/E Ratio | 29.64 | 48.96 | 61% |
| Revenue | 4.82B | 10.6B | 45% |
| Total Cash | 2.42B | 4.52B | 53% |
| Total Debt | 1.39B | 87M | 1,592% |
DXCM | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 65 | |
SMR RATING 1..100 | 27 | 51 | |
PRICE GROWTH RATING 1..100 | 50 | 64 | |
P/E GROWTH RATING 1..100 | 93 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DXCM's Valuation (73) in the Medical Specialties industry is in the same range as ISRG (78). This means that DXCM’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (65) in the Medical Specialties industry is somewhat better than the same rating for DXCM (100). This means that ISRG’s stock grew somewhat faster than DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is in the same range as ISRG (51). This means that DXCM’s stock grew similarly to ISRG’s over the last 12 months.
DXCM's Price Growth Rating (50) in the Medical Specialties industry is in the same range as ISRG (64). This means that DXCM’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (84) in the Medical Specialties industry is in the same range as DXCM (93). This means that ISRG’s stock grew similarly to DXCM’s over the last 12 months.
| DXCM | ISRG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 69% |
| Advances ODDS (%) | 12 days ago 70% | 8 days ago 67% |
| Declines ODDS (%) | 8 days ago 72% | 22 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 65% |
Advertisement
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -0.94% | ||
| BSX - ISRG | 73% Closely correlated | -2.12% | ||
| SYK - ISRG | 64% Loosely correlated | -1.01% | ||
| NTRA - ISRG | 54% Loosely correlated | -1.13% | ||
| GKOS - ISRG | 51% Loosely correlated | +0.39% | ||
| PODD - ISRG | 49% Loosely correlated | -4.66% | ||
More | ||||